

Internationally active ZETA Group acquires a stake in Biotree, India

Biotech cooperation for comprehensive engineering and automation solutions

The biopharmaceutical market in the Asian region shows enormous growth potential. The internationally active ZETA Group has established itself as an end-to-end solution provider for the pharmaceutical and biotech industries in this dynamic environment. With its majority interest in the Indian engineering and plant construction specialist Biotree, ZETA has intensified its development of the Asian market. Local companies benefit from the high quality of their service and performance portfolio.

The **Asian biopharmaceutical market is growing** rapidly. With an annual growth **rate of 13%**, India, is considered an extremely dynamic environment for companies in this industry.

The **international ZETA Group** is also taking advantage of this momentum with its **majority stake in Biotree**, the Indian engineering and plant construction specialist. *"Together, we will intensify our market development in the Asian region and further expand services for our customers, particularly in India and Southeast Asia,"* says **Andreas Marchler, CEO of the ZETA Group** who is well prepared for the future.

Common engineering and supply network

Biotree will be integrated into **ZETA's global engineering and delivery network** and complete the **service portfolio in the Asian region**.

"We are pooling our resources and skills: global presence with engineering, plant construction, and automation hubs in Europe, the USA, and Asia. This is paired with in-depth knowledge of local market requirements," emphasizes **Dr. Anil Paul Kariath, CEO of Biotree**, highlighting the benefits of the partnership.

"It is very important for us to offer our customers in all parts of the world the same expertise and high quality in the fields of engineering, plant construction, automation, and digitalization. With Biotree, we now have an Asian partner on board that fulfills all of these requirements excellently. ZETA is thus consistently implementing the strategy of offering high-quality end-to-end solutions for the pharmaceutical and biotech industry globally, from engineering, construction, automation, digitization to qualification," adds Andreas Marchler in conclusion.

PRESS ZETA

Andreas Pompenig

Team Leader Communication
+43 (664) 808 52 1424
andreas.pompenig@zeta.com

PRESS BIOTREE

Ms. Rinu Kariath

Team Leader Communication
+91 8095616206
Rinu@biotree.co.in

About ZETA

The ZETA Group, with 1200 highly qualified employees and 27 subsidiaries worldwide, specializes in planning, automation, digitalization and qualification of customized biopharmaceutical facilities for aseptic process solutions. ZETA acts as a one-stop shop, combining plant engineering with HVAC and cleanroom design.

Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines and infusions are produced in these highly complex, "tailor-made" facilities. ZETA supports its customers along the entire drug development and manufacturing pathway with sophisticated solutions from laboratory to industrial production scale. Through its Smart Engineering Services, ZETA creates digital twins of process plants and has thus established itself as a market leader for digital solutions in the pharmaceutical and biotech industry.

ZETA is also actively taking steps towards a more sustainable future for the industry as a whole: through ZETA's decarbonization strategies, emissions are specifically reduced during the biopharmaceutical manufacturing process.

About Biotree

BPE Biotree supplies complex bioprocess equipment to biopharmaceutical manufacturing companies, especially in the Asian markets. The company is located at Bangalore, India, employing a current strength of 225 employees.

Since 2012, BPE Biotree has been trusted by customers to design critical equipment to be utilized in the manufacture of biological materials and vaccines in the developing nations. The company provides reliable, precise and high-quality engineering solutions, in accordance with regulatory compliance. BPE Biotree also designs facilities for Biopharmaceutical manufacturing to scale up from laboratory stage to commercial production.

The company strives to foster innovation in the global scientific endeavours through dedication to quality and precision.

Image material

Image credits: Reprint with ZETA copyright notice free of charge



Andreas Marchler, CEO ZETA Group



Dr. Anil Paul Kariath, CEO BPE Biotree



ZETA is an end-to-end solution provider for the pharmaceutical and biotech industries.



Biotree is integrated into ZETA's global engineering and delivery network and completes its service portfolio in the Asian region.